FINWIRES · TerminalLIVE
FINWIRES
$TMO

$TMO

39 stories mentioning TMOUpdated 5d ago

Every FINWIRES story that references TMO, newest first.

Wire

Thermo Fisher Scientific's Strong Q2 Not Enough to 'Meaningfully' Change H2 Outlook, RBC Says

Thermo Fisher Scientific's (TMO) broad-based improvement in Q2 is not enough to "meaningfully" change the forecast for its H2 outlook, RBC Capital Markets said in a Thursday note.The company's "strong" results for the quarter were highlighted by its Analytical Instruments segment exhibiting organic growth of about 7% and segment margin expansion of around 420 basis points driven by electron microscopy and mass spectrometry, the firm said. The Specialty Diagnostics and Lab Products and Biopharma Service segments both beat expectations, while Life Science Solutions was the only segment that did not surpass the consensus estimates, according to the note.Thermo Fisher's four end markets all saw improved customer activity, with the pharma and biotech markets growing a mid-single-digit percentage, and the academic and government market rising by a low-single-digit percentage, the note said.The company's increase of its full-year organic growth guidance to around 4% and adjusted EPS to a range of $24.93 to $25.33 implies little change to the H2 outlook, RBC said.RBC maintained the company's stock rating at sector perform and raised the price target to $580 from $490.Price: $560.87, Change: $-11.46, Percent Change: -2.00%

$TMO
Research

RBC Raises Price Target on Thermo Fisher Scientific to $580 From $490, Keeps Sector Perform Rating

Thermo Fisher Scientific (TMO) has an average rating of overweight and mean price target of $620.75, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

$TMO
Sectors

Sector Update: Healthcare Stocks Rise Late Afternoon

Healthcare stocks advanced late Thursday afternoon with the NYSE Healthcare Index gaining 1.2% and the State Street Health Care Select Sector SPDR ETF (XLV) rising 1.1%.The iShares Biotechnology ETF (IBB) added 1%.In corporate news, Thermo Fisher Scientific (TMO) shares jumped 8.9% after fiscal Q2 adjusted earnings and revenue topped estimates.Quest Diagnostics (DGX) shares rose 8% after Q2 adjusted earnings and revenue exceeded market consensus.Neuphoria Therapeutics (NEUP) agreed to be acquired by Scancell Holdings in an all-stock deal. Neuphoria shares jumped 15%.Agilon Health (AGL) shares fell 14% after Citigroup downgraded the stock to sell from neutral and lifted its price target to $105 from $80.

$AGL$DGX$NEUP$TMO
Wire

Leerink Partners Adjusts Price Target on Thermo Fisher to $620 From $600, Maintains Outperform Rating

Thermo Fisher Scientific (TMO) has an average rating of overweight and mean price target of $595.54, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $574.09, Change: $+47.63, Percent Change: +9.05%

$TMO
Wire

Jefferies Adjusts Price Target on Thermo Fisher Scientific to $630 From $585, Maintains Buy Rating

Thermo Fisher Scientific (TMO) has an average rating of overweight and mean price target of $595.54, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $573.28, Change: $+46.82, Percent Change: +8.89%

$TMO
Sectors

Sector Update: Healthcare Stocks Rise Thursday Afternoon

Healthcare stocks were higher Thursday afternoon, with the NYSE Healthcare Index rising 0.9% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 0.9%.The iShares Biotechnology ETF (IBB) climbed up 1%.In corporate news, Thermo Fisher Scientific (TMO) shares jumped past 8% after it reported higher fiscal Q2 adjusted earnings and revenue.Quest Diagnostics (DGX) shares rose 6.6% after the company reported higher Q2 adjusted earnings and revenue, and raised its 2026 outlook.Neuphoria Therapeutics (NEUP) and Scancell Holdings said Thursday they have struck an all-stock merger deal in which Scancell will acquire Neuphoria. Neuphoria shares surged 20%.Westin Acquisition (WSTN) and First Choice Healthcare Solutions said they have agreed to merge to create a publicly traded healthcare and wellness company. Shares edged up 0.2%.

$DGX$NEUP$TMO$WSTN
Wire

Evercore ISI Adjusts Price Target on Thermo Fisher Scientific to $615 From $570

Thermo Fisher Scientific (TMO) has an average rating of overweight and mean price target of $595.54, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $577.30, Change: $+50.84, Percent Change: +9.66%

$TMO
Sectors

Sector Update: Healthcare Stocks Flat to Higher Premarket Thursday

Healthcare stocks were flat to higher premarket Thursday, with the iShares Biotechnology ETF (IBB) inactive and the State Street Health Care Select Sector SPDR ETF (XLV) up 0.2%.Thermo Fisher Scientific (TMO) shares were up more than 6% after the company reported higher fiscal Q2 adjusted earnings and revenue.West Pharmaceutical Services (WST) stock was up more than 8% after the company posted higher Q2 adjusted earnings and net sales, and increased its 2026 guidance.Quest Diagnostics (DGX) shares were up more than 7% after the company reported higher Q2 adjusted earnings and revenue, and raised its 2026 outlook.

$DGX$IBB$TMO$WST$XLV
Sectors

Sector Update: Healthcare

Healthcare stocks were flat to higher premarket Thursday, with the iShares Biotechnology ETF (IBB) inactive and the State Street Health Care Select Sector SPDR ETF (XLV) up 0.2%.Thermo Fisher Scientific (TMO) shares were up more than 6% after the company reported higher fiscal Q2 adjusted earnings and revenue.

$TMO
Asia Markets

Update: US Equity Futures Drop Pre-Bell as Mid-East Conflict Expands to Potentially Include Red Sea

(Updates with economic data, recent oil price movement, world markets' overview and corporate stock movements.)US equity futures were lower pre-bell Thursday as traders considered the possibility of the Middle East conflict spreading to a new front in the Red Sea, lifting oil prices closer to the $100 mark.Dow Jones Industrial Average futures were 0.6% lower, S&P 500 futures were down 0.8%, and Nasdaq futures were 1.1% lower.The US launched attacks on Iran for the 12th consecutive day, US Central Command said in a post on X. Iran-backed Houthis in Yemen have claimed they attacked two Saudi Arabian oil tankers in the Red Sea for allegedly violating their announced blockade, in a potential new front for the war, according to multiple media reports.Alphabet's (GOOG, GOOGL) Google posted higher earnings and revenue for Q2, but the company's stock dropped 5% in premarket activity as it increased its forecasted capital expenditures to as high as $205 billion.Intel (INTC) is is expected to report its Q2 earnings after the market closes. Analysts polled by FactSet expect earnings of $0.22 per share on revenue of $14.44 billion.Oil prices were higher, with front-month global benchmark North Sea Brent crude up 5.5% at $99.27 per barrel and US West Texas Intermediate crude 4.3% higher at $90.55 per barrel.Initial jobless claims dropped to 187,000 in the week ended July 18 from 209,000 in the previous week, compared with expectations for an increase to 210,000 in a survey compiled by Bloomberg.In other world markets, Japan's Nikkei closed 0.5% higher, Hong Kong's Hang Seng ended 1.3% higher, and China's Shanghai Composite finished 0.3% higher. Meanwhile, the UK's FTSE 100 was down 0.5%, and Germany's DAX index was 0.8% lower in Europe's early afternoon session.In equities, Tesla (TSLA) shares fell 7.6% after the company reported an unexpected year-over-year decline in its Q2 earnings and missing analysts' consensus estimates. T-Mobile US (TMUS) stock was down 5.7% after the company posted lower-than expected Q2 revenue. Texas Instruments (TXN) shares were 4.7% lower despite the company reporting higher Q2 earnings and revenue.On the winning side, RTX (RTX) stock was up 5.9% after the company surpassed consensus estimates for Q2 adjusted earnings and net sales. Thermo Fisher Scientific (TMO) shares rose 5% after the company reported better-than-expected fiscal Q2 adjusted earnings and revenue. Lockheed Martin (LMT) stock was 4.9% higher after the company posted a Q2 beat for earnings and sales, as well as increased its 2026 EPS outlook.

Dow JonesNasdaq CompositeS&P 500$GOOG$GOOGL$INTC$LMT$RTX$TMO$TMUS$TSLA$TXN
Stocks Fall Pre-Bell Amid Rising Middle East Tensions; Traders Parse Alphabet, Tesla Results
US Markets

Stocks Fall Pre-Bell Amid Rising Middle East Tensions; Traders Parse Alphabet, Tesla Results

US equity markets were tracking in the red before the opening bell Thursday and oil prices rose amid escalating tensions in the Middle East, while investors digest the latest financial results of Alphabet (GOOG, GOOGL) and Tesla (TSLA).The S&P 500 and the Dow Jones Industrial Average declined 0.2% each in premarket activity, while the Nasdaq was off 0.3%. The indexes ended the previous trading session mostly down.The Iran-backed Houthi militants in Yemen reportedly claimed attacks on two Saudi Arabian oil tankers in the Red Sea on Wednesday, raising concerns that the conflict could spread to a new front in the Middle East, CNBC reported. The UK Maritime Trade Operations said Wednesday that an "unknown projectile" struck a Saudi Arabian oil tanker around 70 nautical miles southwest of Al Shuqaiq, Saudi Arabia.West Texas Intermediate crude oil climbed 3.7% to $89.99 a barrel before the open, while Brent increased 4.4% to $98.18.The US Central Command said Wednesday its forces struck Iran for the 12th consecutive night. In a social media post, President Donald Trump vowed to destroy an Iranian bridge or power plant every time Tehran attacks ships in the Strait of Hormuz.Iran's Islamic Revolutionary Guard Corps said it hit Jordan's King Faisal and Prince Hassan bases with missiles and drones, claiming to have targeted US military equipment in response to recent American strikes, CNN reported Wednesday.Treasury yields were trending higher in premarket action, with the two-year rate rising 1.3 basis points to 4.32% and the 10-year rate adding 1.8 basis points to 4.68%.Alphabet's (GOOG, GOOGL) class A and C shares were down roughly 4% each pre-bell after the Google parent announced in its second-quarter results that its capital expenditure doubled year over year. Tesla's stock dropped 5.9% as the electric vehicle manufacturer recorded an unexpected year-over-year decrease in its second-quarter earnings amid higher expenses related to research and development and artificial intelligence initiatives.ServiceNow (NOW) jumped 7.6% while IBM (IBM) edged down 0.6% early Thursday following their latest financial results.T-Mobile US (TMUS), Thermo Fisher Scientific (TMO), Union Pacific (UNP), Lockheed Martin (LMT), Blackstone (BX), Comcast (CMCSA) and Honeywell International (HON) are scheduled to release their quarterly earnings before the bell, among others. Intel (INTC) and Deckers Outdoor (DECK) are due to announce their results after the markets close.Thursday's economic calendar has the weekly jobless claims bulletin at 8:30 am ET, along with the Chicago Fed national activity index for June. The Kansas City Fed manufacturing index follows at 11 am.Gold fell 1.5% to $4,092 per troy ounce, while bitcoin slipped 0.2% to $65,732.

Dow JonesNasdaq CompositeS&P 500$BX$CMCSA$DECK$GOOG$GOOGL$HON$IBM$INTC$LMT$NOW$TMO$TMUS$TSLA$UNP
Research

Piper Sandler Initiates Thermo Fisher Scientific at Neutral With $510 Price Target

Thermo Fisher Scientific (TMO) has an average rating of buy and mean price target of $602.50, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

$TMO
Wire

Thermo Fisher Scientific Shares Fall After HSBC Downgrade

Thermo Fisher Scientific (TMO) shares fall 1.6% in Wednesday trading after HSBC downgraded the stock to hold from buy and lowered its price target to $540 From $670.Trading volume stood at about 1 million shares against daily average of 2.3 million.Price: $474.42, Change: $-7.66, Percent Change: -1.59%

$TMO
Research

HSBC Downgrades Thermo Fisher Scientific to Hold From Buy, Adjusts Price Target to $540 From $670

Thermo Fisher Scientific (TMO) has an average rating of buy and mean price target of $602.50, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

$TMO
Sectors

Sector Update: Healthcare Stocks Decline Late Afternoon

Healthcare stocks were lower late Friday afternoon, with the NYSE Healthcare Index falling 1.1% and the State Street Healthcare Select Sector SPDR ETF (XLV) shedding 1%.The iShares Biotechnology ETF (IBB) dropped 2.4%.In corporate news, Thermo Fisher Scientific (TMO) could benefit from improving end-market conditions and recovering biotech funding, though "structural risks" may limit the company's ability to achieve its long-term organic growth aspiration, RBC Capital Markets said in a note. RBC resumed coverage of Thermo Fisher with a sector perform rating and a $490 price target. Thermo Fisher shares were down 2.3%.Aardvark Therapeutics (AARD) shares fell 32% after the firm said the US Food and Drug Administration placed a full clinical hold on its investigational new drug application for ARD-101. Morgan Stanley downgraded the stock to underweight from equalweight, and BTIG downgraded to neutral from buy.DexCom (DXCM) said Friday it has set new long-term financial goals, including organic revenue growth of more than 10% a year through 2030. Its shares climbed past 6%.ARS Pharmaceuticals (SPRY) shares fell 7% after it posted a wider Q1 loss.

$AARD$DXCM$SPRY$TMO
Sectors

Sector Update: Healthcare

Healthcare stocks declined late Friday afternoon, with the NYSE Healthcare Index falling 1.1% and the State Street Healthcare Select Sector SPDR ETF (XLV) shedding 1%.The iShares Biotechnology ETF (IBB) dropped 2.3%.In corporate news, Thermo Fisher Scientific (TMO) could benefit from improving end-market conditions and recovering biotech funding, though "structural risks" may limit the company's ability to achieve its long-term organic growth aspiration, RBC Capital Markets said in a note. RBC resumed coverage of Thermo Fisher with a sector perform rating and a $490 price target. Thermo Fisher shares were down 2.1%.

$TMO
Wire

Thermo Fisher Likely to Benefit From End-Market Recovery, but Structural Risks Remain, RBC Says

Thermo Fisher Scientific (TMO) could benefit from improving end-market conditions and recovering biotech funding, though "structural risks" may limit the company's ability to achieve its long-term organic growth aspiration, RBC Capital Markets said in a report emailed Friday."Investor skepticism" surrounding Thermo Fisher's 2026 guidance and broader post-pandemic recovery trends "is well-founded" after several years of uneven "normalization" across the life sciences tools industry, RBC noted. Still, the firm said recovery prospects appear "more plausible" as uncertainty in large pharmaceutical and academic markets begin to ease.The firm said normalized organic growth closer to 5% may be as likely as management's 7%-plus target and the Wall Street's roughly 6% forecast. It also pointed to "lingering" artificial intelligence uncertainty surrounding the long-term outlook for the company's contract research organization business, which represents about 20% of sales, according to the report.RBC resumed coverage of Thermo Fisher with a sector perform rating and a $490 price target.Price: $442.17, Change: $-6.04, Percent Change: -1.35%

$TMO
Wire

Argus Adjusts Price Target on Thermo Fisher Scientific to $560 From $610

Thermo Fisher Scientific (TMO) has an average rating of buy and mean price target of $623.48, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $470.05, Change: $-8.91, Percent Change: -1.86%

$TMO
Wire

Argus Cuts Price Target on Thermo Fisher Scientific to $560 From $610

Thermo Fisher Scientific (TMO) has an average rating of buy and mean price target of $623.91, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $478.09, Change: $+11.83, Percent Change: +2.54%

$TMO
Wire

Update: Morgan Stanley Lowers Price Target on Thermo Fisher Scientific to $620 From $670, Keeps Overweight Rating

(Updates with the analyst's commentary.)Morgan Stanley lowered its price target on Thermo Fisher Scientific (TMO) to $620 from $670 while maintaining its overweight rating."Investors were clearly looking for more from TMO this quarter, particularly on the topline," Morgan Stanley said in a Monday note.Morgan Stanley said it expects "limited interest" in the company until the "back-half ramp" Thermo Fisher's forecast implies.Thermo Fisher Scientific has an average rating of buy and mean price target of $623.91, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $468.11, Change: $-1.60, Percent Change: -0.34%

$TMO

Showing 1-20 of 39

Track with the FINWIRES app suite